Skip to main content

Advertisement

SpringerLink
Log in

Treatment of Acute Hepatitis B with Nucleoside and/or Nucleotide Analogues

  • Published:
Current Hepatitis Reports Aims and scope Submit manuscript

Abstract

Acute infection with the hepatitis B virus resolves in 95% of adults with no need for specific medical therapy. However, a few cases present as severe hepatitis or acute liver failure, which may require orthotopic liver transplantation or cause death. Under these circumstances, medical therapy that can improve the clinical outcome and improve spontaneous survival would be highly useful; yet, published data regarding the utility of antiviral therapy in acute hepatitis B is quite limited. In this paper, the efficacy and safety of oral nucleoside and nucleotide analogues in the treatment of acute hepatitis B are reviewed, and guidelines for treatment of these acute cases are revisited.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Daniels D, Grytdal S, Wasley A; Centers for Disease Control and Prevention (CDC): Surveillance for acute viral hepatitis—United States, 2007. MMWR Surveill Summ 2009, 58(3):1–27.

    PubMed  Google Scholar 

  2. Schiødt FV, Davern TJ, Shakil AO, et al.: Viral hepatitis-related acute liver failure. Am J Gastroenterol 2003, 98:448–453.

    PubMed  Google Scholar 

  3. Tassopoulos NC, Koutelou MG, Polychronaki H, et al.: Recombinant interferon-alpha therapy for acute hepatitis B: a randomized, double-blind, placebo-controlled trial. J Viral Hepat 1997, 4:387–394.

    Article  CAS  PubMed  Google Scholar 

  4. Kundu SS, Kundu AK, Pal NK: Interferon-alpha in the treatment of acute prolonged hepatitis B virus infection. J Assoc Physicians India 2000, 48:671–673.

    CAS  PubMed  Google Scholar 

  5. Flink HJ, Sprengers D, Hansen BE, et al.: Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut 2005, 54:1604–1609.

    Article  CAS  PubMed  Google Scholar 

  6. Perrillo RP: Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001, 120:1009–1022.

    Article  CAS  PubMed  Google Scholar 

  7. Baumert TF, Thimme R, von Weizsäcker F: Pathogenesis of hepatitis B virus infection. World J Gastroenterol 2007, 13:82–90.

    CAS  PubMed  Google Scholar 

  8. Leifeld L, Cheng S, Ramakers J, et al.: Imbalanced intrahepatic expression of interleukin 12, interferon gamma, and interleukin 10 in fulminant hepatitis B. Hepatology 2002, 36:1001–1008.

    CAS  PubMed  Google Scholar 

  9. Hoofnagle JH, di Bisceglie AM: The treatment of chronic viral hepatitis. N Engl J Med 1997, 336:347–356.

    Article  CAS  PubMed  Google Scholar 

  10. Manns MP: Current state of interferon therapy in the treatment of chronic hepatitis B. Semin Liver Dis 2002, 22(Suppl 1):7–13.

    Article  PubMed  Google Scholar 

  11. Lok AS, Lai CL, Leung N, et al.: Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003, 125:1714–1722.

    Article  CAS  PubMed  Google Scholar 

  12. Reshef R, Sbeit W, Tur-Kaspa R: Lamivudine in the treatment of acute hepatitis B. N Engl J Med 2000, 343:1123–1124.

    Article  CAS  PubMed  Google Scholar 

  13. Chalupa P, Holub M: Favorable outcome of severe acute hepatitis B in a patient treated with antithrombin III and antiviral therapy. Clin Infect Dis 2009, 49:481.

    Article  PubMed  Google Scholar 

  14. Torii N, Hasegawa K, Ogawa M, et al.: Effectiveness and long-term outcome of lamivudine therapy for acute hepatitis B. Hepatol Res 2002, 24:34.

    Article  CAS  PubMed  Google Scholar 

  15. Kondili LA, Osman H, Mutimer D: The use of lamivudine for patients with acute hepatitis B (a series of cases). J Viral Hepat 2004, 11:427–431.

    Article  CAS  PubMed  Google Scholar 

  16. Petrelli E, Balducci M, Pieretti C, et al.: Lamivudine treatment failure in preventing fatal outcome of de novo severe acute hepatitis B in patients with haematological diseases. J Hepatol 2001, 35:823–826.

    Article  CAS  PubMed  Google Scholar 

  17. Wang YC, Kuo MC, Hung CC, et al.: Lamivudine reverses severe acute hepatitis B and pancytopenia after renal transplantation: a case report. Transplant Proc 2006, 38:3125–3127.

    Article  PubMed  Google Scholar 

  18. Haznedar R, Yağci M.: Lamivudine therapy for acute hepatitis B infection following peripheral blood stem cell transplantation. Am J Hematol 2002, 69:151.

    Article  PubMed  Google Scholar 

  19. Nakhoul F, Gelman R, Green J, et al.: Lamivudine therapy for severe acute hepatitis B virus infection after renal transplantation: case report and literature review. Transplant Proc 2001, 33:2948–2949.

    Article  CAS  PubMed  Google Scholar 

  20. Andreone P, Caraceni P, Grazi GL, et al.: Lamivudine treatment for acute hepatitis B after liver transplantation. J Hepatol 1998, 29:985–989.

    Article  CAS  PubMed  Google Scholar 

  21. Efremov DG, Georgievski B, Cevreska L, et al.: Lamivudine treatment for acute hepatitis B virus infection during allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2003, 31:515–516.

    Article  CAS  PubMed  Google Scholar 

  22. Dulai G, Higa L, Kobashigawa J, Martin P: Successful use of lamivudine for severe acute hepatitis B virus infection in a cardiac transplant recipient. Transplantation 1999, 67:1288–1289.

    Article  CAS  PubMed  Google Scholar 

  23. Gupta S, Piraka C, Jaffe M: Lamivudine in the treatment of polyarteritis nodosa associated with acute hepatitis B. N Engl J Med 2001, 344:1645–1646.

    Article  CAS  PubMed  Google Scholar 

  24. Di Marco V, De Lisi S, Li Vecchi M, et al.: Therapy with lamivudine and steroids in a patient with acute hepatitis B and rapidly progressive glomerulonephritis. Kidney Int 2006, 70:1187–1188.

    Article  PubMed  Google Scholar 

  25. Miyake Y, Iwasaki Y, Takaki A, et al.: Lamivudine treatment improves the prognosis of fulminant hepatitis B. Intern Med 2008, 47:1293–1299.

    Article  PubMed  Google Scholar 

  26. Lisotti A, Azzaroli F, Buonfiglioli F, et al.: Lamivudine treatment for severe acute HBV hepatitis. Int J Med Sci 2008, 5:309–312.

    CAS  PubMed  Google Scholar 

  27. Delic D, Nesic Z, Prostran M, et al.: Treatment of subacute hepatitis B with lamivudine: a pilot study in Serbia. Vojnosanit Pregl 2009, 66:199–202.

    PubMed  Google Scholar 

  28. Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E, et al.: Lamivudine treatment for acute severe hepatitis B: a pilot study (published erratum appears in Liver Int 2004, 24:547–551). Liver Int 2004, 24:547–551.

    Article  CAS  PubMed  Google Scholar 

  29. Tillmann HL, Hadem J, Leifeld L, et al.: Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006, 13:256–263.

    Article  CAS  PubMed  Google Scholar 

  30. • Kumar M, Satapathy S, Monga R, et al.: A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007, 45:97–101. This article describes the largest prospective study that evaluated lamivudine therapy in acute hepatitis B, with other larger studies being references 28 and 29.

    Article  CAS  PubMed  Google Scholar 

  31. Girke J, Wedemeyer H, Wiegand J, et al.: Acute hepatitis B: is antiviral therapy indicated? Two case reports [article in German]. Dtsch Med Wochnschr 2008, 133:1178–1182.

    Article  CAS  Google Scholar 

  32. • Palumbo E: Entecavir for chronic hepatitis B: a review. Ther Drug Monit 2008, 30:1–4. This article is a comprehensive review of entecavir, its safety and efficacy, as a treatment for hepatitis B.

    Article  CAS  PubMed  Google Scholar 

  33. • Lange CM, Bojunga J, Hofmann WP, et al.: Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009, 50:2001–2006. This article is a report of severe lactic acidosis in a case series of patients with hepatitis B cirrhosis and significantly impaired liver function while on entecavir therapy.

    Article  CAS  PubMed  Google Scholar 

  34. •• Lok AS, McMahon BJ: Chronic hepatitis B: update 2009. Hepatology 2009, 50:661–662. This article is an updated set of practice guidelines that provide a comprehensive guide to the management of hepatitis B in various populations.

    Article  PubMed  Google Scholar 

Download references

Disclosure

No potential conflict of interest relevant to this article was reported.

Author information

Authors and Affiliations

  1. University of Chicago Medical Center, 5841 South Maryland Avenue, MC 7120, Chicago, IL, 60637, USA

    Helen S. Te

Authors
  1. Helen S. Te
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Helen S. Te.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Te, H.S. Treatment of Acute Hepatitis B with Nucleoside and/or Nucleotide Analogues. Curr Hepatitis Rep 9, 119–123 (2010). https://doi.org/10.1007/s11901-010-0033-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-010-0033-7

Keywords

Search

Navigation